Publicaciones (69) Publicaciones de Eduardo Castañón Álvarez

2024

  1. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study

    Cancer

2022

  1. Bayesian interpretation of immunotherapy trials with dynamic treatment effects

    European Journal of Cancer, Vol. 161, pp. 79-89

  2. Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials

    European Journal of Cancer, Vol. 163, pp. 98-107

  3. MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

    European Journal of Cancer, Vol. 174, pp. S122

  4. Novel strategies exploiting interleukin-12 in cancer immunotherapy

    Pharmacology and Therapeutics, Vol. 239

2021

  1. Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors

    Cancers, Vol. 13, Núm. 15

  2. Cutaneous squamous cell carcinoma presenting with facial paralysis: good response to Cemiplimab

    JDDG - Journal of the German Society of Dermatology

  3. Erratum to “Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings” [Eur J Cancer 136 (September 2020) 159−168] (European Journal of Cancer (2020) 136 (159–168), (S0959804920303300), (10.1016/j.ejca.2020.06.003))

    European Journal of Cancer

  4. Intratumoural administration and tumour tissue targeting of cancer immunotherapies

    Nature Reviews Clinical Oncology, Vol. 18, Núm. 9, pp. 558-576

  5. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

  6. Patterns of progression in patients treated for immuno-oncology antibodies combination

    Cancer Immunology, Immunotherapy, Vol. 70, Núm. 1, pp. 221-232

2020

  1. A Trial of Lopinavir-Ritonavir in Covid-19

    The New England journal of medicine

  2. Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings

    European Journal of Cancer, Vol. 136, pp. 159-168

  3. Does active smoking worsen Covid-19?

    European Journal of Internal Medicine

  4. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors

    OncoImmunology, Vol. 9, Núm. 1

  5. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

    Cancer Medicine, Vol. 9, Núm. 8, pp. 2643-2652

  6. Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy

    Radiologia, Vol. 62, Núm. 2, pp. 131-138

  7. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

  8. Prognostic role of stress cardiac magnetic resonance in the elderly

    Revista Espanola de Cardiologia, Vol. 73, Núm. 3, pp. 241-247

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15